{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:16:17Z","timestamp":1790741777289,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2556,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>The interaction between insulin resistance (IR), steatosis and genotype to fibrosis in chronic hepatitis C virus (HCV) infection has not been comprehensively assessed. We hypothesized that IR is a key mediator for the development of both steatosis and fibrosis in 346 untreated, nondiabetic patients solely infected with either genotype 1 or 3. We examined for genotype-specific interactions between IR, steatosis and fibrosis by performing subgroup analyses. Because cirrhosis is known to cause IR, we repeated the analysis in a cohort of 313 noncirrhotic HCV-infected patients. We confirmed the impact of IR on fibrosis by analysis of 153 lean subjects in whom any effect of steatosis would be minimized. In HCV genotype 3 patients, increased steatosis was linked to high viral load (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.001), and was not associated with fibrosis (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.1). In contrast, body mass index (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.04) and homeostasis model assessment of insulin resistance (HOMA-IR) (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.01) contributed directly to steatosis in HCV genotype 1. HOMA-IR rather than steatosis was independently associated with fibrosis for both HCV genotype 1 (OR, 3.22;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.02) and genotype 3 (OR, 3.17;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.04). Exclusion of cirrhotic subjects did not alter the findings with respect to the greater contribution of IR compared to hepatic steatosis, as a predictor of fibrosis (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.02). Genotype-specific subgroup analyses did not alter this finding. The extent of HOMA-IR remained significantly associated with fibrosis in lean patients, independent of the confounding effect of body mass index on IR (OR, 8.02;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.003).<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>IR is a major independent determinant of fibrosis in chronic HCV infection, regardless of the genotype and the severity of liver damage. (Hepatology 2008.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22392","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T03:16:03Z","timestamp":1209870963000},"page":"723-731","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":93,"title":["Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C"],"prefix":"10.1097","volume":"48","author":[{"given":"Ian Homer Y.","family":"Cua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20241202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/01.mcg.0000135372.10846.2a","article-title":"Obesity and nonalcoholic fatty liver disease in chronic hepatitis C.","volume":"38","author":"Younossi","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"R2-5-20241202","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/hep.1840150403","article-title":"The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis.","volume":"15","author":"Bach","year":"1992","journal-title":"HEPATOLOGY"},{"key":"R3-5-20241202","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0016-5085(93)90432-C","article-title":"Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.","volume":"104","author":"Lefkowitch","year":"1993","journal-title":"Gastroenterology"},{"key":"R4-5-20241202","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment.","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"R5-5-20241202","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2002.33573","article-title":"Nonalcoholic fatty liver disease.","volume":"122","author":"Clark","year":"2002","journal-title":"Gastroenterology"},{"key":"R6-5-20241202","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-2007-1007264","article-title":"Histopathology of hepatitis C virus infection.","volume":"15","author":"Goodman","year":"1995","journal-title":"Semin Liver Dis"},{"key":"R7-5-20241202","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.","volume":"33","author":"Adinolfi","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R8-5-20241202","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/hep.510250340","article-title":"Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype.","volume":"25","author":"Mihm","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R9-5-20241202","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80166-X","article-title":"Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.","volume":"33","author":"RubbiaBrandt","year":"2000","journal-title":"J Hepatol"},{"key":"R10-5-20241202","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/jhep.2003.50267","article-title":"Effect of treatment with peginterferon or interferon alfa2b and ribavirin on steatosis in patients infected with hepatitis C.","volume":"38","author":"Poynard","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R11-5-20241202","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1046\/j.1440-1746.2002.02813.x","article-title":"Genotype specific mechanisms for hepatic steatosis in chronic hepatitis C infection.","volume":"17","author":"Hui","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R12-5-20241202","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/gut.2004.050302","article-title":"Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.","volume":"54","author":"Fartoux","year":"2005","journal-title":"Gut"},{"key":"R13-5-20241202","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1053\/jhep.2002.35064","article-title":"Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.","volume":"36","author":"Monto","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R14-5-20241202","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0168-8278(02)00299-4","article-title":"Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. see comment.","volume":"37","author":"Westin","year":"2002","journal-title":"J Hepatol"},{"key":"R15-5-20241202","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2003.11.004","article-title":"The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.","volume":"40","author":"Patton","year":"2004","journal-title":"J Hepatol"},{"key":"R16-5-20241202","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2893.2004.00528.x","article-title":"Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.","volume":"11","author":"Hezode","year":"2004","journal-title":"J Viral Hepat"},{"key":"R17-5-20241202","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.2002.009936","article-title":"Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.","volume":"53","author":"Castera","year":"2004","journal-title":"Gut"},{"key":"R18-5-20241202","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1053\/jhep.2002.36370","article-title":"Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response.","volume":"36","author":"Kumar","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R19-5-20241202","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.510290401","article-title":"Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis.","volume":"29","author":"Hourigan","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R20-5-20241202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.20983","article-title":"Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.","volume":"43","author":"Camma","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R21-5-20241202","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gut.52.9.1386","article-title":"Worsening of steatosis and fibrosis progression. comment.","volume":"52","author":"Ratziu","year":"2003","journal-title":"Gut"},{"key":"R22-5-20241202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C.","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"R23-5-20241202","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1016\/S0002-9343(99)00374-5","article-title":"Natural history of hepatitis C.","volume":"107","author":"Seeff","year":"1999","journal-title":"Am J Med"},{"key":"R24-5-20241202","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1365-2893.2002.00340.x","article-title":"Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model.","volume":"9","author":"DeufficBurban","year":"2002","journal-title":"J Viral Hepat"},{"key":"R25-5-20241202","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/j.1572-0241.2002.05995.x","article-title":"Contribution of obesity to hepatitis Crelated fibrosis progression.","volume":"97","author":"Ortiz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R26-5-20241202","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. corrected.","volume":"125","author":"Hui","year":"2003","journal-title":"Gastroenterology"},{"key":"R27-5-20241202","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/j.1572-0241.2002.05793.x","article-title":"Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C.","volume":"97","author":"Serfaty","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R28-5-20241202","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/hep.510280330","article-title":"Impact of alcohol on the histological and clinical progression of hepatitis C infection.","volume":"28","author":"Wiley","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R29-5-20241202","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/gut.2003.018770","article-title":"Steatosis affects chronic hepatitis C progression in a genotype specific way.","volume":"53","author":"RubbiaBrandt","year":"2004","journal-title":"Gut"},{"key":"R30-5-20241202","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1053\/j.gastro.2006.03.014","article-title":"Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data.","volume":"130","author":"Leandro","year":"2006","journal-title":"Gastroenterology"},{"key":"R31-5-20241202","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1440-1746.2001.02407.x","article-title":"Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation.","volume":"16","author":"Hwang","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R32-5-20241202","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0168-8278(98)80004-4","article-title":"Host and diseasespecific factors affecting steatosis in chronic hepatitis C.","volume":"29","author":"Czaja","year":"1998","journal-title":"J Hepatol"},{"key":"R33-5-20241202","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.52.2.288","article-title":"Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.","volume":"52","author":"Castera","year":"2003","journal-title":"Gut"},{"key":"R34-5-20241202","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20750","article-title":"Steatosis: cofactor in other liver diseases.","volume":"42","author":"Powell","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R35-5-20241202","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R36-5-20241202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00400692","article-title":"Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and nondiabetic cirrhotic patients.","volume":"36","author":"Kruszynska","year":"1993","journal-title":"Diabetologia"},{"key":"R37-5-20241202","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gut.2003.021691","article-title":"Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.","volume":"53","author":"Ryder","year":"2004","journal-title":"Gut"},{"key":"R38-5-20241202","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hep.21078","article-title":"Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.","volume":"43","author":"Perumalswami","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R39-5-20241202","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.20207","article-title":"Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index.","volume":"39","author":"Hui","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R40-5-20241202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2004.09.022","article-title":"Insulin resistance is associated with liver fibrosis in nondiabetic chronic hepatitis C patients.","volume":"42","author":"Muzzi","year":"2005","journal-title":"J Hepatol"},{"key":"R41-5-20241202","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"key":"R42-5-20241202","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0168-8278(03)00456-2","article-title":"Fibrogenic impact of high serum glucose in chronic hepatitis C.","volume":"39","author":"Ratziu","year":"2003","journal-title":"J Hepatol"},{"key":"R43-5-20241202","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0168-8278(03)00463-X","article-title":"In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.","volume":"39","author":"Hickman","year":"2003","journal-title":"J Hepatol"},{"key":"R44-5-20241202","first-page":"1384","article-title":"Impaired IRS1PI3kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.","volume":"38","author":"Aytug","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R45-5-20241202","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0002-9440(10)63408-6","article-title":"Hepatitis C virus downregulates insulin receptor substrates 1 and 2 through upregulation of suppressor of cytokine signaling 3.","volume":"165","author":"Kawaguchi","year":"2004","journal-title":"Am J Pathol"},{"key":"R46-5-20241202","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2003.11.056","article-title":"Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.","volume":"126","author":"Shintani","year":"2004","journal-title":"Gastroenterology"},{"key":"R47-5-20241202","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/hep.510300425","article-title":"Expression of connective tissue growth factor in experimental rat and human liver fibrosis.","volume":"30","author":"Paradis","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R48-5-20241202","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/jhep.2001.28055","article-title":"High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis.","volume":"34","author":"Paradis","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R49-5-20241202","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.21429","article-title":"Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.","volume":"44","author":"Bugianesi","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R50-5-20241202","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/gut.52.11.1638","article-title":"Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C.","volume":"52","author":"Asselah","year":"2003","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22392","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200809000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T17:05:05Z","timestamp":1733159105000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200809000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22392","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}